Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx

Mercy Research

Overview

The purpose of this study is to examine treatment method of Methicillin-resistant Staphylococcus aureus (MRSA) decolonization in patients.

Decolonization therapy is indicated for management of patients with MRSA. Theraworx is reported to be an effective antimicrobial against multiple organisms. In this study, patients with positive MRSA colonization culture will be treated with Theraworx to evaluate decolonization duration capability.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Methicillin-Resistant Staphylococcus Aureus

Interventions

TheraworxOTHER

Theraworx swab intranasal BID for 5 days

mupirocin antibiotic ointmentDRUG

mupirocin antibiotic ointment swab intranasal BID for 5 days

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Positive MRSA culture Exclusion Criteria: * Patients currently on or start antibiotic therapy directed for MRSA.(Prophylaxis antibiotic for surgical procedure not considered therapy.) * Patients with MRSA infected wounds * Patients under the age of 18 years * A woman currently pregnant or nursing a child * Patients participating in another study within 30 days of randomization

Outcomes

Primary Outcomes

Evidence of decolonization confirmed by intranasal culture

Time frame: Up to 14 days post treatment (+/- 1-2 days)

Secondary Outcomes

Economic-Cost comparison of treatment Evidence of decolonization

Time frame: 5 days of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.